0R19.LSE Becton Dickinson & Co.
- Market cap
- -
- P/E
- 31.5x
- P/B
- -
- ROE
- 2.4%
- Dividend yield
- 0.01%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is 0R19.LSE undervalued?
Graham numberThe Graham number of Becton Dickinson & Co. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Becton Dickinson & Co. fundamental analysis
No fundamental analysis for Becton Dickinson & Co. yet.
Becton Dickinson & Co. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Becton Dickinson & Co.
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, …
Full company profileBecton Dickinson & Co. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Becton Dickinson & Co. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 12.5B | 12.1B | 16.0B | 16.2B | 16.1B | 19.1B | 18.9B | 19.4B | 20.2B | 21.8B | 19.9B |
| Gross Profit | 5.99B | 5.94B | 7.27B | 7.50B | 6.80B | 8.63B | 8.48B | 8.82B | 9.13B | 9.92B | 9.17B |
| Operating Income | 2.16B | 2.17B | 2.25B | 2.31B | 1.57B | 2.63B | 2.51B | 2.11B | 3.09B | 2.58B | 2.87B |
| EBITDA | 3.21B | 2.44B | 3.73B | 5.07B | 2.97B | 4.25B | 4.29B | 4.28B | 4.68B | 4.81B | 4.98B |
| Net Income | 976M | 1.10B | 311M | 1.23B | 874M | 2.09B | 1.78B | 1.48B | 1.71B | 1.68B | 597M |
| EPS | 4.49 | 4.92 | 1.18 | 4.49 | 3.09 | 7.16 | 6.19 | 5.15 | 5.86 | 5.84 | 2.17 |
| Balance Sheet | |||||||||||
| Total Assets | 25.6B | 37.7B | 53.9B | 51.8B | 54.0B | 53.9B | 52.9B | 52.8B | 57.3B | 55.3B | 50.7B |
| Total Liabilities | 18.0B | 24.8B | 32.9B | 30.7B | 30.2B | 30.2B | 27.7B | 27.0B | 31.4B | 29.9B | 26.3B |
| Shareholders' Equity | 7.63B | 12.9B | 21.0B | 21.1B | 23.8B | 23.7B | 25.3B | 25.8B | 25.9B | 25.4B | 24.4B |
| Cash & Short-term Investments | 1.57B | 14.2B | 1.25B | 620M | 2.94B | 2.40B | 1.17B | 1.42B | 2.30B | 859M | 864M |
| Total Debt | 11.6B | 18.9B | 21.5B | 19.4B | 18.4B | 18.1B | 16.6B | 16.4B | 21.1B | 20.7B | 16.8B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 2.56B | 2.55B | 2.87B | 3.33B | 3.50B | 4.65B | 2.63B | 2.99B | 3.80B | 3.43B | 2.54B |
| Capital Expenditure | 718M | 727M | 895M | 957M | 769M | 1.19B | 973M | 874M | 725M | 760M | 501M |
| Free Cash Flow | 1.84B | 1.82B | 1.97B | 2.37B | 2.73B | 3.45B | 1.66B | 2.12B | 3.07B | 2.67B | 2.04B |
| Ratios | |||||||||||
| ROE | 12.8% | 8.5% | 1.5% | 5.8% | 3.7% | 8.8% | 7.0% | 5.8% | 6.6% | 6.6% | 2.4% |
| ROA | 3.8% | 2.9% | 0.6% | 2.4% | 1.6% | 3.9% | 3.4% | 2.8% | 3.0% | 3.0% | 1.2% |
| Net Profit Margin | 7.8% | 9.1% | 1.9% | 7.6% | 5.4% | 10.9% | 9.4% | 7.7% | 8.4% | 7.7% | 3.0% |
| Debt to Equity | 1.51x | 1.46x | 1.02x | 0.92x | 0.77x | 0.76x | 0.66x | 0.64x | 0.81x | 0.82x | 0.69x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Becton Dickinson & Co. dividends
- Dividend yield
- 0.01%
- Forward dividend
- -
- Payout ratio
- 71.3%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | 1.20B | 4.17 | 71.3% |
| 2024 | USD 1.10B | 3.78 | 64.5% |
| 2023 | USD 1.11B | 3.86 | 75.1% |
| 2022 | USD 1.08B | 3.77 | 60.8% |
| 2021 | USD 1.05B | 3.59 | 50.1% |
| 2020 | USD 1.03B | 3.63 | 117.4% |
| 2019 | USD 984M | 3.58 | 79.8% |
| 2018 | USD 927M | 3.50 | 298.1% |
| 2017 | USD 677M | 3.03 | 61.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Becton Dickinson & Co.
- Insiders 0.43%
- Institutions 99.57%
- Public & others 0.00%
- Free float 272M
Becton Dickinson & Co. company profile
- Company name
- Becton Dickinson & Co.
- Ticker
- 0R19.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 72,000
- Fiscal year end
- September
- Address
- 1 Becton Drive, Franklin Lakes, NJ, United States, 07417-1880
- Phone
- 201 847 6800
- Website
- bd.com
About Becton Dickinson & Co.
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Becton Dickinson & Co. management
10- Mr. Thomas E. Polen Jr.President, CEO & Chairman · born 1973
- Mr. Michael C. FeldExecutive VP & Chief Revenue Officer · born 1981
- Mr. Vitor RoqueExecutive VP & CFO · born 1983
- Ms. Elizabeth McCombsExecutive VP & CTO · born 1977
- Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D.Senior VP & Chief Scientific Officer
- Mr. Arthur HuExecutive VP and Chief Information & Digital Officer
- Mr. Shawn C. BevecSenior Vice President of Investor Relations
- Ms. Lanesha T. Minnix J.D.Executive VP & General Counsel · born 1975
- Carla BurigattoSenior VP & Chief Communications Officer
- Ms. Meera GopalakrishnanSenior VP & Global Chief Marketing Officer